Alzheimer’s disease portal contains vast amounts of data
The National Institutes of Health (NIH) has introduced a portal that includes Alzheimer’s disease data that researchers can share and analyze to help them design clinical trials and evaluate therapeutic targets.
The resource is part of the Accelerating Medicines Partnership between NIH, the U.S. Food and Drug Administration, 10 biopharmaceutical companies and several non-profit organizations.
Sage Bionetworks developed the portal, which includes data from more than 2,000 postmortem brain samples. The program is expected to last five years, during which Sage Bionetworks data scientists will work with academic and industry researchers.
“We are determined to reduce the cost and time it takes to discover viable therapeutic targets and bring new diagnostics and effective therapies to people with Alzheimer’s. That demands a new way of doing business,” said NIH Director Francis S. Collins, MD, PhD, in a news release. “The AD initiative of AMP is one way we can revolutionize Alzheimer’s research and drug development by applying the principles of open science to the use and analysis of large and complex human datasets.”
Executive Editor
Tim Casey joined TriMed Media Group in 2015 as Executive Editor. For the previous four years, he worked as an editor and writer for HMP Communications, primarily focused on covering managed care issues and reporting from medical and health care conferences. He was also a staff reporter at the Sacramento Bee for more than four years covering professional, college and high school sports. He earned his undergraduate degree in psychology from the University of Notre Dame and his MBA degree from Georgetown University.